J&J Didn't Warn Of Risperdal Breast-Growth Risk, Jury Told
A treating physician told a Philadelphia jury on Monday that a Johnson & Johnson unit had not informed him about the risks associated with the antipsychotic drug Risperdal before he prescribed...To view the full article, register now.
Already a subscriber? Click here to view full article